Innovation for acute coronary syndrome patients
The Miracor PICSO® technology holds the promise to improve the outcomes after stenting/PCI in acute coronary syndrome patients.
Miracor Medical Systems GmbH has developed and will commercialize the Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO®) technology for heart attack patients. The PICSO® technology redistributes blood flow into the damaged tissue of the heart which can reduce and revitalize the damaged tissue. The technology is in European clinical trials and Miracor is targeting a European product launch in 2011. On our Web pages you will learn more about Miracor, the PICSO® technology and future applications in interventional cardiology.
news
receive news alerts
Last updated: 29/06/10Miracor Medical Systems GmbH, Mariannengasse 14/14, A-1090 Vienna Austria · t +43 (0) 1 - 236 657 612 · f +43 (0) 1 - 236 657 622 · picso[at]miracormedical.com
